Psychiatric Unit and DEGRA Centre, United Hospital of Ancona and Academic Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Via Conca, 71, 60020, Ancona, Italy.
Clin Drug Investig. 2013 Sep;33(9):685-8. doi: 10.1007/s40261-013-0112-y.
Maternal psychiatric disorders can have negative consequences on the fetus and newborn. Thus, the risks of untreated mental disorders in pregnancy should be balanced against the potential risks of a psychopharmacological treatment. The aim of the present report is to provide information on the infant safety of duloxetine exposure, an antidepressant drug belonging to the serotonin-norepinephrine reuptake inhibitors, during pregnancy. Despite duloxetine being routinely prescribed as a treatment for major depression and anxiety disorders, there is a paucity of literature evaluating both the short- and long-term effects of duloxetine exposure in utero. This paper provides data on infant health and neurodevelopmental outcomes, up to 9 months of age, in a newborn exposed to duloxetine throughout pregnancy. Although the present report suggests that duloxetine was not associated with major malformations or neurobehavioural problems, the drug should be used with caution until further information is available on its safety profile in pregnancy.
母亲的精神疾病会对胎儿和新生儿产生负面影响。因此，应该权衡未经治疗的精神障碍在妊娠期间的风险与精神药物治疗的潜在风险。本报告的目的是提供有关在怀孕期间使用度洛西汀（一种属于 5-羟色胺-去甲肾上腺素再摄取抑制剂的抗抑郁药）的婴儿安全性的信息。尽管度洛西汀通常被规定用于治疗重度抑郁症和焦虑症，但评估度洛西汀在子宫内的短期和长期影响的文献很少。本文提供了在妊娠期间持续暴露于度洛西汀的新生儿的婴儿健康和神经发育结果的数据，直到 9 个月大。尽管本报告表明度洛西汀与重大畸形或神经行为问题无关，但在获得更多关于其在妊娠期间安全性特征的信息之前，应谨慎使用该药物。
